These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 17433121)
1. Outcome measures in clinical trials on medicinal products for the treatment of dementia: a European regulatory perspective. Broich K Int Psychogeriatr; 2007 Jun; 19(3):509-24. PubMed ID: 17433121 [TBL] [Abstract][Full Text] [Related]
2. Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia. Molnar FJ; Man-Son-Hing M; Fergusson D J Am Geriatr Soc; 2009 Mar; 57(3):536-46. PubMed ID: 19187414 [TBL] [Abstract][Full Text] [Related]
3. International Psychogeriatric Association consensus statement on defining and measuring treatment benefits in dementia. Katona C; Livingston G; Cooper C; Ames D; Brodaty H; Chiu E Int Psychogeriatr; 2007 Jun; 19(3):345-54. PubMed ID: 17386120 [TBL] [Abstract][Full Text] [Related]
4. Global measures: utility in defining and measuring treatment response in dementia. Reisberg B Int Psychogeriatr; 2007 Jun; 19(3):421-56. PubMed ID: 17480241 [TBL] [Abstract][Full Text] [Related]
5. Clinical trials in predementia stages of Alzheimer disease. Pillai JA; Cummings JL Med Clin North Am; 2013 May; 97(3):439-57. PubMed ID: 23642580 [TBL] [Abstract][Full Text] [Related]
6. Slowing the progression of Alzheimer disease: methodologic issues. Leber P Alzheimer Dis Assoc Disord; 1997; 11 Suppl 5():S10-21; discussion S37-9. PubMed ID: 9348423 [TBL] [Abstract][Full Text] [Related]
7. Biomarkers in clinical trials for neurodegenerative diseases: regulatory perspectives and requirements. Broich K; Weiergräber M; Hampel H Prog Neurobiol; 2011 Dec; 95(4):498-500. PubMed ID: 21945642 [TBL] [Abstract][Full Text] [Related]
8. The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint. Mani RB Stat Med; 2004 Jan; 23(2):305-14. PubMed ID: 14716731 [TBL] [Abstract][Full Text] [Related]
9. Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe Alzheimer's disease. Gauthier S; Lopez OL; Waldemar G; Jones RW; Cummings J; Zhang R; Schindler R; Schwam E Int Psychogeriatr; 2010 Sep; 22(6):973-83. PubMed ID: 20534179 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date. Bullock R Alzheimer Dis Assoc Disord; 2006; 20(1):23-9. PubMed ID: 16493232 [TBL] [Abstract][Full Text] [Related]
11. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506 [TBL] [Abstract][Full Text] [Related]
12. Cholinesterase inhibitors in the treatment of Alzheimer's disease and related dementias. Masterman D Clin Geriatr Med; 2004 Feb; 20(1):59-68. PubMed ID: 15062487 [No Abstract] [Full Text] [Related]
13. Structural neuroimaging outcomes in clinical dementia trials, with special reference to disease modifying designs. Scheltens P; Barkhof F J Nutr Health Aging; 2006; 10(2):123-8; discussion 129-30. PubMed ID: 16554946 [TBL] [Abstract][Full Text] [Related]
14. Cognitive pharmacotherapy of Alzheimer's disease and other dementias. Herrmann N Can J Psychiatry; 2002 Oct; 47(8):715-22. PubMed ID: 12420649 [TBL] [Abstract][Full Text] [Related]
15. Outcomes for clinical trials in mild-to-moderate dementia to evaluate drugs with presumably symptomatic effects. Frolich L J Nutr Health Aging; 2007; 11(4):357-8. PubMed ID: 17653499 [No Abstract] [Full Text] [Related]
16. Report of the European Working Group on Dementia Drug Guidelines Meeting--Brussels, November 1997. Harvey RJ; Whitehouse PJ; Rossor MN Alzheimer Dis Assoc Disord; 1998 Dec; 12(4):259-61. PubMed ID: 9876953 [TBL] [Abstract][Full Text] [Related]
17. A review of the randomized controlled trials of tacrine in the treatment of Alzheimer's disease: methodologic considerations. Conway EL Clin Neuropharmacol; 1998; 21(1):8-17. PubMed ID: 9579280 [TBL] [Abstract][Full Text] [Related]
18. Protocols to demonstrate slowing of Alzheimer disease progression. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. The Disease Progression Sub-Group. Bodick N; Forette F; Hadler D; Harvey RJ; Leber P; McKeith IG; Riekkinen PJ; Rossor MN; Scheltens P; Shimohama S; Spiegel R; Tanaka S; Thal LJ; Urata Y; Whitehouse P; Wilcock G Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():50-3. PubMed ID: 9305517 [TBL] [Abstract][Full Text] [Related]
19. Clinical trial designs for demonstrating disease-course-altering effects in dementia. Whitehouse PJ; Kittner B; Roessner M; Rossor M; Sano M; Thal L; Winblad B Alzheimer Dis Assoc Disord; 1998 Dec; 12(4):281-94. PubMed ID: 9876956 [TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study. Gutzmann H; Kühl KP; Hadler D; Rapp MA Pharmacopsychiatry; 2002 Jan; 35(1):12-8. PubMed ID: 11819153 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]